admin – Page 4236 – Get News Story

Advanced Cervical Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

DelveInsight’s, “Advanced Cervical Cancer Pipeline Insight” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Advanced Cervical Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Advanced Liver Cancer Treatment Landscape. Click here to read more @ Advanced Liver Cancer Pipeline Outlook

Key Takeaways from the Advanced Cervical Cancer Pipeline Report

In January 2025:- Merck Sharp & Dohme LLC:- The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival and overall survival.
In January 2025:- AstraZeneca:- A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical). Women with locally advanced cervical cancer will be randomized in a 1:1 ratio to receive treatment with Volrustomig or Placebo.
In January 2025:- DualityBio Inc.:- This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a study. Phase 1 adopts the standard “3+3” design to identify: the MTD and/or RP2D of DB-1310 as monotherapy, the RCD_A of DB-1310 in combination with trastuzumab and the RCD_B of DB-1310 in combination with Osimertinib; Phase 2a is a dose expansion phase to confirm the safety, tolerability and explore efficacy in selected malignant solid tumors treated with DB-1310 as monotherapy or in combination with trastuzumab or in combination with Osimertinib.
In January 2025:- RAPT Therapeutics Inc.:- The study will be conducted in 2 parts, a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2). In Part 1 of the study, subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy or in combination with pembrolizumab. In Part 2 of the study, subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 as monotherapy or in combination with pembrolizumab.
In January 2025:- Amgen:- The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Advanced Cervical Cancer treatment.
The leading Advanced Cervical Cancer Companies such as AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.
Promising Advanced Cervical Cancer Pipeline Therapies such as Durvalumab, Cisplatin, Carboplatin, IBI310, and others.

Stay informed about the cutting-edge advancements in Advanced Cervical Cancer treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Cervical Cancer Clinical Trials Assessment

Advanced Cervical Cancer Emerging Drugs Profile

Imfinzi (durvalumab): AstraZeneca

Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. Imfinzi is the only approved immunotherapy in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy, and is the global standard of care in this setting based on the PACIFIC Phase III trial. Imfinzi is also approved in the US, EU, Japan, China and many other countries around the world for the treatment of extensive-stage small cell lung cancer based on the CASPIAN Phase III trial. As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with small cell lung cancer, NSCLC, bladder cancer, several gastrointestinal cancers, ovarian cancer, endometrial cancer and other solid tumours. Currently, it is in Phase III stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.

Dostarlimab: GlaxoSmithKline

Dostarlimab is a humanised PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. Currently, it is in Phase II stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.

Andes 1537: Andes Biotechnologies

Andes-1537, a proprietary antisense oligonucleotide designed by Andes Biotechnology, is the Company’s most advanced investigational drug candidate and the first to enter a human clinical study. It targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. Upon administration, Andes-1537 binds to a specific ncmtRNA, inducing cell cycle arrest and apoptosis of cancer cells. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Cervical Cancer.

Learn more about Advanced Cervical Cancer Drugs opportunities in our groundbreaking Advanced Cervical Cancer Research and development projects @ Advanced Cervical Cancer Unmet Needs

Advanced Cervical Cancer Companies

AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.

Advanced Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.

Advanced Cervical Cancer Pipeline Products have been categorized under various Molecule types such as-

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Discover the latest advancements in Advanced Cervical Cancer treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Cervical Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Advanced Cervical Cancer Pipeline Report

Coverage- Global
Advanced Cervical Cancer Companies- AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.
Advanced Cervical Cancer Pipeline Therapies- Durvalumab, Cisplatin, Carboplatin, IBI310, and others.
Advanced Cervical Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Advanced Cervical Cancer Therapeutics Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Cervical Cancer Pipeline on our website @ Advanced Cervical Cancer Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
Advanced Cervical Cancer: Overview
Advanced Cervical Cancer Pipeline Therapeutics
Advanced Cervical Cancer Therapeutic Assessment
Advanced Cervical Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Advanced Cervical Cancer Collaboration Deals
Late Stage Products (Phase III)
Durvalumab: AstraZeneca
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Dostarlimab: GlaxoSmithKline
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Andes 1537: Andes Biotechnologies
Drug profiles in the detailed report…..
Inactive Products
Advanced Cervical Cancer Key Companies
Advanced Cervical Cancer Key Products
Advanced Cervical Cancer- Unmet Needs
Advanced Cervical Cancer- Market Drivers and Barriers
Advanced Cervical Cancer- Future Perspectives and Conclusion
Advanced Cervical Cancer Analyst Views
Advanced Cervical Cancer Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/surgical-mask-respirator-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Cervical Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

Netherlands – 125 Existing Data Center Facilities & 40 Data Center Operators Details Analyzed – Arizton

Digital Realty and Equinix are the top data center operators in the Netherlands market

Arizton published latest research on the Netherlands existing & upcoming data center portfolio.

Get Exclusive Insight on the Database Now: https://www.arizton.com/market-reports/netherlands-data-center-portfolio

Netherlands Data Center Market Database Report Scope

Number of Existing Facilities: 125

Number of Upcoming Facilities: 11

This database covers the Netherlands data center market portfolio analysis, which will provide the following information on the colocation data centers:

Detailed Analysis of 125 existing data centers
Detailed Analysis of 11 upcoming data centers
Location covered: Aalsmeer, Almere, Almere, Alphen aan den Rijn, Amsterdam, Apeldoorn, Arnhem, Delft, Deventer, Dronten, Ede, Eemshaven, Eindhoven, Enschede, Geleen, Gemert, Goes, Groningen, Haarlem, Hague, Hengelo, Hilversum, Hoogersmilde, IJsselstein, Leeuwarden, Lelystad, Limburg, Loon op Zand, Maastricht, Markelo, Megen, Meppel, Mierlo, Naaldwijk, Nieuwegein, Oude Meer, Roermond, Roosendaal, Rotterdam, s-Hertogenbosch, Steenbergen, Tjerkgaast, Ugchelen, Utrecht, Waalwijk, Wormer, Zwolle.
Existing white-floor space (square feet)
Upcoming white-floor space (square feet)
Current IT load capacity (2024)
Future capacity additions (2025-2028)
Retail Colocation Pricing
Quarter Rack (1/4)
Half Rack Cabinets (1/2)
Full Rack Cabinet (42U/45U/47U/etc.)
Wholesale colocation (per kW) pricing

We Get in Touch with Industry Experts Across the Following Categories:

Data Center Contractors/Sub-Contractors (Civil, Engineering, Architecture, and others)
Data Center System Integrators (Power/Cooling/Physical Security/Fire Suppression-Detection Systems)
Data Center Developers (Colocation Service Providers)
Data Center Infrastructure Providers

Netherlands Existing & Upcoming Data Center Market Report Insights

The data center market in the Netherlands is characterized by a significant gap between existing and upcoming capacity, with current IT power capacity almost double that of the anticipated new data centers. The market is primarily dominated by leading operators such as Digital Realty and Equinix, both of whom hold substantial shares in the country. Amsterdam stands out as the focal point, with around 90% of the upcoming rack capacity concentrated in the city. Existing data centers, which number 125 facilities, provide a detailed snapshot of the market, including key information such as the location, operator or owner, facility name, white-floor area, IT load capacity, rack capacity, year of operations, design standards (ranging from Tier I to Tier IV), and the redundancy levels for power and cooling systems. Meanwhile, 11 upcoming data centers are currently under development or in the planning stages. These projects are accompanied by detailed investment snapshots, including breakdowns for electrical, mechanical, and construction infrastructure investments, as well as the expected opening year. This comprehensive data highlights both the current state and the projected growth of the data center market in the Netherlands, with Amsterdam continuing to be the central hub for new developments.

Looking for More Information? Click: https://www.arizton.com/market-reports/netherlands-data-center-portfolio

Target Audience

Data Center Real Estate Investment Trusts (REIT)
Data Center Construction Contractors
Data Center Infrastructure Providers
New Entrants
Consultants/Consultancies/Advisory Firms
Corporate and Governments Agencies

About Our Data Center Capabilities  

Arizton’s team of principal consultants and analysts work towards publishing extensive secondary and primary research that is credible, resourceful, and data driven. With over 5 years of experience, Arizton has helped several Fortune 500 companies with data-driven insights that enabled them to expand their businesses to niche regions, added over a billion dollars in revenues, and effective go-to-market strategies. We offer various product portfolios to meet the clients’ requirements, which align with their key business strategies and identify high-value growth avenues.  

Exhaustive syndicated reports, databases, country-wise market analysis, & customized consulting projects are published by our team of exuberant and well-experienced analysts who possess exemplary skills in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research. Subscribe to our exhaustive portfolios to gain access to premium research reports at competitive prices. Partner with Arizton for your next strategic business decision and gain a competitive advantage with real-time, data-driven research.  

About Us:                                                  

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                 

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                       

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/netherlands-data-center-portfolio

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Netherlands – 125 Existing Data Center Facilities & 40 Data Center Operators Details Analyzed – Arizton

Profit for Veterans Launches to Support Disabled First Responders and Veterans

New Initiative Donates 100% of Book Profits to Assist Heroes Transitioning to Civilian Success.

Profit for Veterans, founded by retired executive, educator, and entrepreneur Martin Lund, has officially launched with a mission to support veterans and first responders. The initiative donates 100% of profits from Lund’s books to programs that help these individuals overcome challenges and build successful post-service lives.

With a distinguished career spanning corporate leadership, education, and real estate investment, Martin Lund brings decades of experience to this philanthropic endeavor. His books, Foreclosure Solutions: The Ultimate Guide to Foreclosure Defense and How to Buy and Sell Foreclosure Homes for Profit, provide invaluable financial insights based on his firsthand expertise. By directing all proceeds from these publications toward assisting veterans and first responders, Profit for Veterans aims to empower those who have sacrificed for their country and communities.

Through this initiative, the organization focuses on providing financial literacy, career resources, and support programs that enable disabled veterans and first responders to thrive. Many of these individuals face unique challenges as they transition to civilian life, and Profit for Veterans seeks to bridge the gap with practical assistance and opportunities for long-term success.

Lund’s extensive background in business and education informs his approach to this mission. He previously served as Chief Financial Officer and Board Member at Tiffany & Company for two decades before shifting into real estate, where he specialized in acquiring and selling distressed properties. In addition to his executive experience, he has taught at New York University and the American Real Estate School, sharing his knowledge with aspiring professionals.

The two books at the center of this initiative offer a comprehensive guide to navigating foreclosure and real estate investment. Foreclosure Solutions: The Ultimate Guide to Foreclosure Defense serves as a step-by-step manual for homeowners facing foreclosure, as well as professionals assisting them. How to Buy and Sell Foreclosure Homes for Profit provides expert strategies for those interested in real estate investment, focusing on maximizing profitability while minimizing risk. Both books are available in Kindle editions on Amazon.

“Our veterans and first responders have given so much to serve and protect us. Profit for Veterans is my way of giving back, using my experience and resources to provide real, tangible support,” said Martin Lund. “Every book purchased is more than just a financial guide—it’s a direct contribution to helping these heroes build successful futures.”

By purchasing these books, readers not only gain valuable knowledge but also contribute to a cause that makes a real difference. Profit for Veterans is committed to using these proceeds to fund meaningful initiatives that equip veterans and first responders with the skills and opportunities they need to succeed.

For more information visit https://profitforveterans.com.

Media Contact
Company Name: Profit for Veterans
Contact Person: Martin Lund
Email: Send Email
Phone: 516-319-5487
Country: United States
Website: https://profitforveterans.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Profit for Veterans Launches to Support Disabled First Responders and Veterans

Advanced Liver Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

DelveInsight’s, “Advanced Liver Cancer Pipeline Insight” Report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced liver cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Liver Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Advanced Liver Cancer Treatment Landscape. Click here to read more @ Advanced Liver Cancer Pipeline Outlook

Key Takeaways from the Advanced Liver Cancer Pipeline Report

In January 2025:- Hoffmann-La Roche:- This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.
In January 2025:-Tango Pharmaceuticals Inc.:- This is a Phase 1/2 multi-center, open label study in solid tumor patients who have a confirmed homozygous MTAP deletion in their tumor. The Phase 1 portion is a dose escalation study of oral TNG462 administered as a single agent and in combination with pembrolizumab in patients with confirmed MTAP-deleted solid tumors. In Phase 2, 6 expansion arms defined by confirmed MTAP-deleted tumor types will enroll in parallel at the RP2D(s) of TNG462 and in combination. In both parts of the study participants who tolerate the drug may continue treatment until disease progression.
In January 2025:- AstraZeneca:- This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participaants with advanced unresectable HCC. Participants must not have received any prior systemic therapy for HCC. Participants may have previously received locoregional therapy (LRT) but must no longer be suitable for additional LRT. Any local treatment needs to have been completed at least 4 weeks prior to initiation of treatment. The study consists of 4 periods: screening (Day-28 to Day -1), Treatment period, safety follow-up and survival follow-up.
In January 2025:- Polaris Group:- Safety will be evaluated by laboratory tests, vital sign measurements, physical examinations and subject medical history which will be performed to detect new abnormalities and any deterioration in pre-existing conditions. Efficacy will be determined by overall survival, progression free survival, pharmacodynamics (peripheral blood arginine and citrulline levels) and immunogenicity (antibodies to ADI-PEG 20).
DelveInsight’s Advanced Liver Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Liver Cancer treatment.
The leading Advanced Liver Cancer Companies such as Can-Fite BioPharma, Polaris Pharmaceuticals, SOTIO Biotech, Surface Oncology, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AstraZeneca, Takeda, Arbele, ImmVira Pharma Co. Ltd, Vaxcell Bio, Eutilex, Biocity Biopharmaceutics Co., Ltd., Qilu Pharmaceutical Co., Ltd., OriCell Therapeutics Co., Ltd., TORL Biotherapeutics, LLC, Shanghai Henlius Biotech, TaiRx, Inc., Biocity Biopharmaceutics Co., Ltd., and others.
Promising Advanced Liver Cancer Therapies such as Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Parsaclisib, AV-299, Zimberelimab, Domvanalimab, and others.

Stay informed about the cutting-edge advancements in Advanced Liver Cancer treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Liver Cancer Clinical Trials Assessment

Advanced Liver Cancer Emerging Drugs Profile

Namodenoson: Can-Fite BioPharma

Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5′- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). Namodenoson’s mechanism of action is mediated via deregulation of the NF-?B and Wnt signal transduction pathways, resulting in the apoptosis of tumor cells. The protective effect of Namodenoson is mediated via down-regulation of the NF-kB signal transduction pathway and preventing apoptosis. Namodenoson has a potent anti-cancer effect, particularly against hepatocellular carcinoma, and anti-inflammatory activity demonstrated in pre-clinical animal models of liver inflammation. Currently, the drug is in Phase III stage of its development for the treatment of Advanced liver Cancer.

ADI-PEG20: Polaris Pharmaceuticals

Pegylated arginine deiminase (ADI-PEG20) is a novel anticancer enzyme that produces depletion of arginine, which is a nonessential amino acid in humans. Certain tumors, such as malignant melanoma and hepatocellular carcinoma, are auxotrophic for arginine. These tumors that are sensitive to arginine depletion do not express argininosuccinate synthetase, a key enzyme in the synthesis of arginine from citrulline. ADI-PEG20 appears to show inhibitory effects on human melanomas and hepatocellular carcinomas. Currently, the drug is in Phase III stage of its development for the treatment of Advanced liver Cancer.

SRF388: Surface Oncology

SRF388 is a fully human IgG1 blocking antibody to IL-27 with potential to promote immune activation in the tumor microenvironment. The immunoregulatory cytokine IL-27 upregulates inhibitory immune checkpoint receptors (eg, PD-L1, TIGIT) and downregulates proinflammatory cytokines (eg, IFN?, TNFa). Currently, the drug is in the Phase II stage of development to treat Advanced liver cancer.

TQB2223: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

TQB2223 is a recombinant, fully human antibody that binds to lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production. Currently, the drug is in the Phase I stage of development to treat Advanced liver cancer.

Learn more about Advanced Liver Cancer Drugs opportunities in our groundbreaking Advanced Liver Cancer Research and development projects @ Advanced Liver Cancer Unmet Needs

Advanced Liver Cancer Companies

Can-Fite BioPharma, Polaris Pharmaceuticals, SOTIO Biotech, Surface Oncology, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AstraZeneca, Takeda, Arbele, ImmVira Pharma Co. Ltd, Vaxcell Bio, Eutilex, Biocity Biopharmaceutics Co., Ltd., Qilu Pharmaceutical Co., Ltd., OriCell Therapeutics Co., Ltd., TORL Biotherapeutics, LLC, Shanghai Henlius Biotech, TaiRx, Inc., Biocity Biopharmaceutics Co., Ltd, and others.

Advanced liver cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Advanced Liver Cancer Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Discover the latest advancements in Advanced Liver Cancer treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Liver Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Advanced Liver Cancer Pipeline Report

Coverage- Global
Advanced Liver Cancer Companies- Can-Fite BioPharma, Polaris Pharmaceuticals, SOTIO Biotech, Surface Oncology, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AstraZeneca, Takeda, Arbele, ImmVira Pharma Co. Ltd, Vaxcell Bio, Eutilex, Biocity Biopharmaceutics Co., Ltd., Qilu Pharmaceutical Co., Ltd., OriCell Therapeutics Co., Ltd., TORL Biotherapeutics, LLC, Shanghai Henlius Biotech, TaiRx, Inc., Biocity Biopharmaceutics Co., Ltd., and others.
Advanced Liver Cancer Therapies- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Parsaclisib, AV-299, Zimberelimab, Domvanalimab, and others.
Advanced Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Advanced Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Liver Cancer Pipeline on our website @ Advanced Liver Cancer Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
Advanced liver cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Advanced liver cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Namodenoson: Can-Fite BioPharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Product Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
TQB2223: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Advanced liver cancer Key Companies
Advanced liver cancer Key Products
Advanced liver cancer- Unmet Needs
Advanced liver cancer- Market Drivers and Barriers
Advanced liver cancer- Future Perspectives and Conclusion
Advanced liver cancer Analyst Views
Advanced liver cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Liver Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

Metastatic Breast Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Metastatic Breast Cancer pipeline landscape. It covers the Metastatic Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Metastatic Breast Cancer Research. Learn more about our innovative pipeline today! @ Metastatic Breast Cancer Pipeline Outlook

Key takeaways from the Metastatic Breast Cancer Pipeline Report

In January 2025:- Oncolytics Biotech:- The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy [paclitaxel] and avelumab in treating a type of breast cancer called Hormone Receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 negative(HER2-) breast cancer, which is either locally advanced or has metastasized (cancer that has spread in your body). The study will investigate if pelareorep in combination with paclitaxel and avelumab is more effective than paclitaxel alone, or pelareorep and paclitaxel. The safety of the combination treatments will also be evaluated.
In January 2025:- Eli Lilly and Company:- The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.
In January 2025:- Allarity Therapeutics:- The Phase 2 study is using 2x-121 DRP® biomarker in metastatic breast cancer patients to identify patients likely to respond to and benefit from treatment with 2X-121. 2X-121 is a small molecule targeted inhibitor of Poly ADP ribose polymerase (PARP), a key enzyme involved in DNA damage repair in cancer cells. The PARP inhibitor demonstrated clinical activity in a prior Phase 1 study in a number of solid tumors. 2X-121 has a novel dual-inhibitory action against both PARP 1/2 and Tankyrase 1/2. The molecule is also active in P-glycoprotein expressing cells, suggesting it may overcome some of the PARP inhibitor resistance.
DelveInsight’s Metastatic Breast Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Metastatic Breast Cancer treatment.
The leading Metastatic Breast Cancer Companies working in the market include Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd., Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme, Inc., Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., and Taizhou Hanzhong biomedical co. Ltd, and others.
Promising Metastatic Breast Cancer therapies in the various stages of development include Tucatinib, Capecitabine, Trastuzumab, Palifosfamide, Bavituximab, NK105, Paclitaxel, Navelbine, Herceptin, and others

Stay informed about the cutting-edge advancements in Metastatic Breast Cancer treatments. Download for updates and be a part of the revolution in care @ Metastatic Breast Cancer Clinical Trials Assessment

Metastatic Breast Cancer Emerging Drugs Profile

Giredestrant: Roche

Giredestrant is a next generation investigational Selective estrogen receptor degrader (SERD), designed to fully block ER signalling with robust receptor occupancy. Oestrogen encourages HR-positive breast cancer cells to grow by attaching to the ER. Giredestrant works by blocking this receptor to prevent the action of oestrogen, and in the process causes the receptor to be degraded. This investigational medicine has also shown efficacy regardless of ESR1 mutation status (mutations in the ESR1 gene are important mechanisms of resistance to hormone therapy).

Disitamab Vedotin: RemeGen

Disitamab Vedotin (RC48) is a novel anti-HER2 antibody-drug conjugate (ADC) which is currently across various solid tumor types. It was the first domestically-developed ADC in China approved by the CDE for clinical development in China. ADCs are a therapeutic modality consisting of an antibody molecule linked to a highly cytotoxic agent, and is typically designed to specifically deliver chemotherapies to tumor cells.

EndoTAG®-1 (SB05): SynCore Biotechnology

SB05 is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with newly developing, negatively charged endothelial cells, which are especially required for the growth of tumor blood vessels. The SB05 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting the blood supply to tumors without affecting the supply to not activated endothelial cells of healthy tissue. By doing this, SB05 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth.

Stenoparib (2X-121): Allarity Therapeutics

Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. Given its novel mechanism of action and ability to cross the blood brain barrier (BBB), plus its associated DRP®, stenoparib is poised to yield improved efficacy, lower toxicity, and lower drug resistance compared the other late-stage or marketed PARP inhibitors.

Learn more about Metastatic Breast Cancer Drugs opportunities in our groundbreaking Metastatic Breast Cancer Research and development projects @ Metastatic Breast Cancer Unmet Needs

Metastatic Breast Cancer Companies

Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd., Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme, Inc., Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., and Taizhou Hanzhong biomedical co. Ltd, and others.

Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type

Metastatic Breast Cancer Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Discover the latest advancements in Metastatic Breast Cancer treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Metastatic Breast Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Metastatic Breast Cancer Pipeline Report

Coverage- Global
Metastatic Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Metastatic Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Metastatic Breast Cancer Companies- Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd., Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme, Inc., Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., and Taizhou Hanzhong biomedical co. Ltd, and others.
Metastatic Breast Cancer Therapies- Tucatinib, Capecitabine, Trastuzumab, Palifosfamide, Bavituximab, NK105, Paclitaxel, Navelbine, Herceptin, and others.

For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Breast Cancer Pipeline on our website @ Metastatic Breast Cancer Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
Metastatic Breast Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Metastatic Breast Cancer – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Giredestrant: Roche
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Stenoparib – Allarity Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
ARV-471: Arvinas
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Metastatic Breast Cancer Key Companies
Metastatic Breast Cancer Key Products
Metastatic Breast Cancer- Unmet Needs
Metastatic Breast Cancer- Market Drivers and Barriers
Metastatic Breast Cancer- Future Perspectives and Conclusion
Metastatic Breast Cancer Analyst Views
Metastatic Breast Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Breast Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

Gold Terra Resources (TSX: YGT.V) Launches 2025 Drilling Program(s) for High-Grade Gold – More Stocks Inside!

Gold Terra Resource Corp. (TSX.V: YGT) (OTCQB: YGTFF) has officially commenced its 2025 wedge hole drilling program, continuing its aggressive exploration of the prolific Campbell Shear (CS) from master hole GTCM24-056 on the Con Mine Option (CMO) Property. The master hole, drilled to a depth of 3,002 metres, will serve as a foundation for multiple wedge offshoots, allowing for an efficient and cost-effective evaluation of the CS at depths up to 600 metres below the Robertson Shaft at 1,900 metres.

Gold Terra Advances Deep Exploration Strategy

The primary objective of this advanced drilling initiative is to test for high-grade gold mineralization in the CS, which has a historic production record of 5.1 Moz at an average grade of 16 g/t (refer to the Oct. 21, 2022, Technical Report). By leveraging wedge drilling, the company aims to unlock new gold ounces at depth while maximizing cost-efficiency compared to traditional surface drilling methods.

The CMO Property, currently under option from a subsidiary of Newmont Corporation, remains 100% acquirable by Gold Terra upon meeting specific conditions outlined in the CMO Property Option Agreement (refer to the Company’s news release dated November 22, 2021). The target zone for the drilling campaign lies between 1,900 and 2,600 metres in elevation, downdip from the historically mined 5.1 Moz deposit, in a steep southward plunge.

Yellowknife Project: A Premier High-Grade Gold Camp

The Yellowknife Project (YP) spans 918 sq. km in the Northwest Territories, strategically positioned near Yellowknife. The company controls one of Canada’s six major high-grade gold camps, leveraging key infrastructure such as roads, air transport, hydroelectric power, and skilled labor. Gold Terra is actively drilling the Campbell Shear, a gold-rich structure with historic production of 14 Moz, including the Con Mine Option (CMO) property, which produced 6.1 Moz (1938-2003). YP and CMO cover 70 km of the Yellowknife greenstone belt, hosting past-producing Con and Giant gold mines.

CEO Gerald Panneton Highlights Expansion Potential

Gold Terra’s Chairman and CEO, Gerald Panneton, emphasized the significance of this drilling initiative: “Building on our success in 2024, we are excited to start the 2025 wedge hole drilling program to assess the high-grade gold potential of the Campbell Shear below the Robertson Shaft. This drilling method is both efficient and cost-effective, allowing us to explore a large, under-explored area 600 to 800 metres below existing infrastructure. Our goal is to continue adding high-grade gold ounces to our upcoming Mineral Resource Estimate (MRE).”

Gold Terra’s Vision for Re-Establishing Yellowknife as a Premier Gold Mining District

Situated within the prolific Yellowknife greenstone belt, the YP and CMO properties cover nearly 70 kilometers of mineralized shear zones, hosting the former-producing Con and Giant gold mines. Gold Terra’s exploration efforts have identified substantial gold mineralization zones, with numerous high-potential targets still awaiting testing. The company remains steadfast in its mission to restore Yellowknife’s status as one of Canada’s top-tier gold mining jurisdictions.

Other High-Growth Stocks Making Waves:

MGO Global, Inc. (MGOL): operates as a lifestyle brand portfolio company, focusing on fashion design, brand development, and management, notably associated with the Messi brand.

NanoVibronix, Inc. (NAOV): is a medical device company specializing in non-invasive biological response-activating devices that target wound healing and pain therapy.

Sacks Parente Golf, Inc. (SPGC): designs and manufactures high-performance golf equipment, including putters and shafts, aiming to enhance player performance through innovative technology.

Power Nickel Inc. (PNPN.V): Hits 52-week highs in Canada and the US today, drawing increased investor interest and continues to expand the Lion Zone and capitalize on rising demand across precious and base metals. Stay tuned for updates as this project progresses and remains a standout in a resilient precious metals market.

With small-cap stocks gaining traction amid growing investor interest in mining, technology and biotech sectors, YGT.V, MGOL, NAOV, SPGC, and PNPN.V are among the stocks to watch as momentum builds.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gold Terra Resources (TSX: YGT.V) Launches 2025 Drilling Program(s) for High-Grade Gold – More Stocks Inside!

J Weeks Entertainment Presents “Dear Darryl: A Letter to My Father” at Conyers Rockdale Council for the Arts

New Stage Production Explores the Complex Journey from Boyhood to Manhood.

J Weeks Entertainment announces its latest theatrical production, “Dear Darryl: A Letter to My Father,” scheduled for March 14, 15, and 16 at the Conyers Rockdale Council for the Arts. The production aims to bring attention to themes of identity, resilience, and the often-unspoken realities that arise from growing up without a father figure. The show marks an important milestone for J Weeks Entertainment, which has built a reputation for creating impactful stage plays that resonate with diverse audiences.

In this one-act play, the narrative follows the protagonist through three stages of life, capturing moments of innocence, growing confidence, and ultimate perseverance. This progression offers a poignant depiction of how individuals adapt and find strength despite the loss or absence of a father.

The story introduces characters such as Young Weeks (an adolescent representation of J Weeks), J-Rod (the teenage version), and J Weeks (the adult man who confronts his struggles as a father and husband). These perspectives illustrate how the absence of a paternal figure does not define a person’s worth, but rather serves as a catalyst for growth, self-discovery, and finding power in one’s own choices.

The production is set to take place at 910 Center Street Northeast, Conyers, GA 30012, a location known for its commitment to community engagement and the arts. Audience members will be invited to immerse themselves in the lives of characters like Do-Right, a man who once had everything but lost it all, and Quameh Rico, a neighborhood hero grappling with a street-life past while aspiring to build a new legacy through business. Through these intertwined stories, “Dear Darryl: A Letter to My Father” underscores the universal quest for acceptance, the importance of confronting unresolved trauma, and the journey from boyhood to manhood.

“A boy does what he wants to do… A man does what he has to do,” commented J Weeks, reflecting on the play’s deeper message of responsibility and growth. J Weeks Entertainment was established in 2010 to provide grassroots artists with a platform for creative expression. Its theatrical productions seek to empower audiences and raise social awareness, consistently delivering thought-provoking performances that spark meaningful conversations in the community.

Tickets for “Dear Darryl: A Letter to My Father” are available through Eventbrite at https://www.eventbrite.com/e/dear-darryl-stage-play-tickets-1218690148039?aff=oddtdtcreator. Media outlets are encouraged to cover this event to help foster wider discussions about identity, resilience, and the responsibilities that come with stepping into adulthood. Interviews and press opportunities are available upon request.

For more information on J Weeks Entertainment visit https://www.jweeksentertainment.com.

About J Weeks Entertainment

J Weeks Entertainment was created in 2010 to offer grassroots artists a space to showcase their talents through theater and the arts. By focusing on real-life issues that resonate with the community, the company uses the stage as a platform to inspire, encourage thoughtful reflection, and ignite transformative change.

Media Contact
Company Name: J Weeks Entertainment
Contact Person: J Weeks
Email: Send Email
Phone: 301-846-8580
Country: United States
Website: https://www.jweeksentertainment.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: J Weeks Entertainment Presents “Dear Darryl: A Letter to My Father” at Conyers Rockdale Council for the Arts

The UK Data Center Market Research Analysis 2030: Get Insights on 227 Existing Data Centers & 39 Upcoming Facilities – Arizton

“UK Data Center Market Research Report by Arizton”

According to Arizton’s latest research report, the United Kingdom data center market is growing at a CAGR of 13.33% during 2025-2030.

Looking for More Information? Click: https://www.arizton.com/market-reports/uk-data-center-market-investment-analysis

Report Scope:     

Market Size – Investment (2030): $22.65 Billion         

Market Size – Area (2030): 2.19 Million Sq. Ft.

Market Size – Power Capacity (2030): 462 MW

CAGR – Investment (2024-2030): 13.33%    

Colocation Market Size – Revenue (2030): $8.84 Billion

Historic Year: 2021-2023             

Base Year: 2024           

Forecast Year: 2025-2030             

UK Data Center Market Overview

The UK is emerging as a leading hub for data center investments in Europe, driven by the increasing adoption of cloud services, rising internet penetration, and strong government support. Significant investments are being made by both local and international data center providers, including hyperscale operators like AWS, Microsoft, Google, and others, who are establishing new cloud regions in the country. The UK’s data protection laws, such as the Data Protection Act and GDPR, have further encouraged local data storage compliance, boosting data center growth.

Key developments include large-scale investments in infrastructure, like AWS’s planned $10.45 billion investment in data centers over the next five years, and Google’s $1 billion investment in a new data center in Waltham Cross. There are also notable partnerships, such as Vodafone and Microsoft’s $1.5 billion collaboration to enhance cloud services and AI.

The UK’s connectivity is bolstered by 56 existing submarine cables, with new cables like the Beaufort and IOEMA cables set to expand global connectivity. Additionally, the government is focused on enhancing broadband infrastructure and supporting digital access nationwide.

Technological advancements, particularly in AI, IoT, big data, and 5G networks, are driving demand for data centers, as is the rapid growth of mobile and social media use. These trends are accelerating the digital transformation across sectors such as healthcare, finance, and government, positioning the UK as a major player in the data center market.

The UK Pioneers Renewable Energy and Data Center Growth

The UK is progressing towards generating 95% of its electricity from renewables by 2030, with 43% of energy already sourced from renewables as of September 2024. London aims for over 15% renewable energy by 2030 to support its carbon neutrality target by 2050. This renewable shift is fostering the growth of data centers, as companies adopt sustainable energy solutions. Notable examples include Amazon’s deal to acquire 159 MW of energy from the East Anglia Three offshore wind farm, and Iron Mountain’s plan to source 5 MW of rooftop solar for its LON-1 data center.

The demand for renewable power is driving the expansion of data centers across the country, with major projects like VIRTUS Data Centres, DC01UK, and Kao Data developing facilities with significant IT capacities. These efforts, alongside grid improvements by Octopus Energy and Global Switch, support the UK’s dual goals of sustainability and enhanced digital infrastructure.

Growth of Colocation Data Centers in the UK

The UK is a prominent hub for colocation data centers in Europe, with a strong concentration of facilities, particularly in London. Major operators like Digital Realty, Equinix, CyrusOne, and Telehouse are key players in the market, and the growing demand for cloud services and the expansion of hyperscale operations are expected to significantly increase colocation capacity in the coming years. In recent times, several companies have made substantial investments to develop new data centers across the country. Notable examples include major US-based firms, which have poured billions into the UK’s data center infrastructure. The demand for colocation services is primarily driven by the cloud and IT sectors, with additional interest from industries like banking, finance, and government. While the high-end colocation market continues to grow, the lower-end segment, offering smaller-scale services, is expected to shrink as consolidation within the industry progresses.

London: A Prime Hub for Data Center Development

London is a major hub for data center development in the UK, driven by its strong financial sector, dynamic digital economy, and advanced infrastructure. With more than 50 data center facilities in the city, London hosts leading providers like Digital Realty, Equinix, and CyrusOne, catering to sectors like finance, media, and entertainment. The city’s adoption of cloud-based services and advanced technologies such as AI, big data, and IoT continues to accelerate.

In 2024, London saw the development of around 22 new data centers, mostly in the colocation sector. Key investors like VIRTUS Data Centres, Vantage Data Centers, and Echelon Data Centres are contributing to this growth. Notable initiatives include Queen Mary University of London’s collaboration with Schneider Electric to implement a heat recovery system, repurposing waste heat for campus buildings. The city is also exploring supercomputing technologies, with plans to deploy Nvidia GPUs in data centers.

Why Should You Buy this Research?

Market size available in the investment, area, power capacity, and UK colocation market revenue.
An assessment of the data center investment in the UK by colocation, hyperscale, and enterprise operators.
Data center investments in the area (square feet) and power capacity (MW) across counties in the country.
A detailed study of the existing UK data center market landscape, an in-depth industry analysis, and insightful predictions about the UK data center market size during the forecast period.
Snapshot of existing and upcoming third-party data center facilities in the UK
Facilities Covered (Existing): 227
Facilities Identified (Upcoming): 39
Coverage: 34+ Counties
Existing vs. Upcoming (Data Center Area)
Existing vs. Upcoming (IT Load Capacity)
Data center colocation market in the UK
Colocation Market Revenue & Forecast (2021-2030)
Retail vs Wholesale Colocation Market Revenue & Forecast (2021-2030)
Retail & Wholesale Colocation Pricing
The UK data center landscape market investments are classified into IT, power, cooling, and general construction services with sizing and forecast.
A comprehensive analysis of the latest trends, growth rate, potential opportunities, growth restraints, and prospects for the industry.
Business overview and product offerings of prominent IT infrastructure providers, construction contractors, support infrastructure providers, and investors operating in the industry.
A transparent research methodology and analysis of the demand and supply aspects of the industry.

Book the Free Sample Now: https://www.arizton.com/market-reports/uk-data-center-market-investment-analysis

The Report Includes the Investment in the Following Areas:

IT Infrastructure

Servers
Storage Systems
Network Infrastructure

Electrical Infrastructure

UPS Systems
Generators
Transfer Switches & Switchgears
PDUs
Other Electrical Infrastructure

Mechanical Infrastructure

Cooling Systems
Rack Cabinets
Other Mechanical Infrastructure

Cooling Systems

CRAC & CRAH Units
Chiller Units
Cooling Towers, Condensers & Dry Coolers
Other Cooling Units

General Construction

Core & Shell Development
Installation & Commissioning Services
Engineering & Building Design
Fire Detection & Suppression Systems
Physical Security
Data Center Infrastructure Management (DCIM)

Tier Standard

Tier I & Tier II
Tier III
Tier IV

Geography

Greater London
Other Counties

Vendor Landscape

IT Infrastructure Providers

Arista Networks
Atos
Broadcom
Cisco Systems
Dell Technologies
Fujitsu
Hewlett Packard Enterprise
Huawei Technologies
IBM
Juniper Networks
NetApp

Data Center Construction Contractors & Sub-Contractors

2bm
AECOM
Arup
ARC:MC
AtkinsRéalis
BladeRoom Data Centres
Bouygues Construction
Deerns
Future-tech
HDR Architecture
INFINITI IT
ISG
JCA Engineering
Kirby Group Engineering
ACIES Civil and Structural
Mace Group
Mercury
MiCiM
StudioNWA
Sweet Projects
RED Engineering Design
SPIE
Skanska
STO Building Group
Sudlows
TTSP
Waldeck

Support Infrastructure Providers

ABB
Airedale
Caterpillar
Cummins
Delta Electronics
Eaton
Kohler
Legrand
Mitsubishi Electric
Pillar Power Systems
Rittal
Rolls-Royce
Riello Elettronica Group
Schneider Electric
Siemens
Socomec
STULZ
Vertiv
AF Switchgear
AVK

Data Center Investors

Amazon Web Services
Ark Data Centres
Colt Data Centre Services
CyrusOne
Datum
Digital Realty
Echelon Data Centres
Equinix
Global Switch
Google
Green Mountain
Iron Mountain
Kao Data
Microsoft
nLighten
NTT DATA
Pure Data Centres
Telehouse
Vantage Data Centers
VIRTUS Data Centres
Yondr Group

New Entrants

Ada Infrastructure
CloudHQ
Digital Reef
Global Technical Realty
Humber Tech Park
J Mould Reading
SEGRO
Latos
QTS Data Centers
EdgeNebula

Key Questions Answered in the Report:     

How many existing and upcoming data center facilities exist in the UK?

How big is the UK data center market?

How much MW of power capacity will be added across the UK during 2025-2030?

What factors are driving the UK data center market?

Who are the key investors in the UK data center market?

Check Out Some of the Top Selling Research Reports:   

Spain Data Center Market – Investment Analysis & Growth Opportunities 2025-2030

https://www.arizton.com/market-reports/spain-data-center-market-investment-analysis-report

Germany Data Center Market – Investment Analysis & Growth Opportunities 2024-2029

https://www.arizton.com/market-reports/germany-data-center-market-2025

Why Arizton?                                              

100% Customer Satisfaction                                              

24×7 availability – we are always there when you need us                                              

200+ Fortune 500 Companies trust Arizton’s report                                              

80% of our reports are exclusive and first in the industry                                              

100% more data and analysis                                              

1500+ reports published till date                            

Post-Purchase Benefit                                          

1hr of free analyst discussion                                          
10% off on customization

About Us:                                                                                   

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The UK Data Center Market Research Analysis 2030: Get Insights on 227 Existing Data Centers & 39 Upcoming Facilities – Arizton

T-Cell Acute Lymphoblastic Leukemia FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

DelveInsight’s, “T-Cell Acute Lymphoblastic Leukemia Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in T-Cell Acute Lymphoblastic Leukemia pipeline landscape. It covers the T-Cell Acute Lymphoblastic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the T-Cell Acute Lymphoblastic Leukemia Treatment Landscape. Click here to read more @ T-Cell Acute Lymphoblastic Leukemia Pipeline Outlook

Key Takeaways from the T-Cell Acute Lymphoblastic Leukemia Pipeline Report

In January 2025:- Beam Therapeutics Inc.:– This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to < 12 years), and a Phase 2 cohort.
DelveInsight’s T-Cell Acute Lymphoblastic Leukemia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for T-Cell Acute Lymphoblastic Leukemia treatment.
The leading T-Cell Acute Lymphoblastic Leukemia Companies such as Ascentawits Pharmaceuticals, Wugen, Jazz Pharmaceuticals, iCellGene Therapeutics, HebeiSenlangBiotechnology, Nanjing Bioheng Biotech, and others.
Promising T-Cell Acute Lymphoblastic Leukemia Therapies such as WU-CART-007, LY3039478, Dexamethasone, Vincristine, Daunorubicin, and others.

Stay informed about the cutting-edge advancements in T-Cell Acute Lymphoblastic Leukemia treatments. Download for updates and be a part of the revolution in cancer care @ T-Cell Acute Lymphoblastic Leukemia Clinical Trials Assessment

T-Cell Acute Lymphoblastic Leukemia Emerging Drugs Profile

AST-3424: Ascentawits Pharmaceuticals

AST-3424 is a first-in-class small molecule coupled targeted drug developed by the Aixindawei R&D team that relies on AKR1C3 enzyme activation. It selectively cleaves the aldehyde-keto reductase family 1 member C3 (AKR1C3) into a cytotoxic active form (AST-2660). The diaziridine (AST-2660) released by AST-3424 is similar to the standard chemotherapy drugs thiotepa and mitomycin C, which alkylates and cross-links DNA at the N7 (or O6) position of guanine, leading to cell death. SWOG was commissioned by the National Cancer Institute (NCI) to conduct a Phase II clinical study of relapsed and refractory T-ALL. The Phase II clinical study of relapsed and refractory T-ALL is a single-arm, open-label, OBI-3424 monotherapy (one treatment cycle every 21 days, with administration on the 1st and 8th days) led by SWOG (Southwest Oncology Group) with the National Cancer Institute as the main sponsor. The commercial rights for AST-3424 outside of Asia belong to the company’s global partner OBI. Currently, the drug is in Phase II stage of its development for the treatment of T-ALL.

WU-CART-007: Wugen

WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies. WU-CART-007 is manufactured using healthy donor-derived T-cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. WU-CART-007 is currently being evaluated in a global Phase I/II clinical trial for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL). WU-CART-007 has received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the U.S. Food and Drug Administration for the treatment of R/R T-ALL/LBL.

Learn more about T-Cell Acute Lymphoblastic Leukemia Drugs opportunities in our groundbreaking Melanoma research and development projects @ T-Cell Acute Lymphoblastic Leukemia Unmet Needs

T-Cell Acute Lymphoblastic Leukemia Companies

Ascentawits Pharmaceuticals, Wugen, Jazz Pharmaceuticals, iCellGene Therapeutics, HebeiSenlangBiotechnology, Nanjing Bioheng Biotech, and others.

T-Cell Acute Lymphoblastic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.

T-Cell Acute Lymphoblastic Leukemia Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Discover the latest advancements in T-Cell Acute Lymphoblastic Leukemia treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ T-Cell Acute Lymphoblastic Leukemia Market Drivers and Barriers, and Future Perspectives

Scope of the T-Cell Acute Lymphoblastic Leukemia Pipeline Report

Coverage- Global
T-Cell Acute Lymphoblastic Leukemia Companies- Ascentawits Pharmaceuticals, Wugen, Jazz Pharmaceuticals, iCellGene Therapeutics, HebeiSenlangBiotechnology, Nanjing Bioheng Biotech, and others.
T-Cell Acute Lymphoblastic Leukemia Therapies- WU-CART-007, LY3039478, Dexamethasone, Vincristine, Daunorubicin, and others.
T-Cell Acute Lymphoblastic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
T-Cell Acute Lymphoblastic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of T-Cell Acute Lymphoblastic Leukemia Pipeline on our website @ T-Cell Acute Lymphoblastic Leukemia Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
T-Cell Acute Lymphoblastic Leukemia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Drug Name: Company Name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
AST-3424: Ascentawits Pharmaceuticals
Drug profiles in the detailed report…..
Early stage products (Phase I)
WU-CART-007: Wugen
Drug profiles in the detailed report…..
Inactive Products
T-Cell Acute Lymphoblastic Leukemia Key Companies
T-Cell Acute Lymphoblastic Leukemia Key Products
T-Cell Acute Lymphoblastic Leukemia- Unmet Needs
T-Cell Acute Lymphoblastic Leukemia- Market Drivers and Barriers
T-Cell Acute Lymphoblastic Leukemia- Future Perspectives and Conclusion
T-Cell Acute Lymphoblastic Leukemia Analyst Views
T-Cell Acute Lymphoblastic Leukemia Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: T-Cell Acute Lymphoblastic Leukemia FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

B2B Digital Payment Market Recent Trends, Outlook, Size, Share, Top Companies, Industry Analysis, Future Development & Forecast – 2028

“PayPal (US), Fiserv (US), FIS (US), Global Payments (US), ACI Worldwide (US), Block (US), MasterCard (US), Visa (US), Payoneer (US), Stripe (US), Helcim (Canada), Payset (UK), Paytm (India), Razorpay (India), Rapyd (UK).”

B2B Digital Payment Market by Offering (Solutions, Services), Payment Method (Credit Cards/Debit Cards/Virtual Cards, Digital Wallet), Transaction Type (Domestic, Cross-Border), Vertical and Region – Global Forecast to 2028.

The B2B digital payment market is expected to expand from USD 4.2 billion in 2023 to USD 8.2 billion by 2028, reflecting a CAGR of 14.3% over the forecast period. These digital payment solutions provide a quicker and more efficient alternative to conventional paper-based transactions. By leveraging electronic payments, businesses can streamline processing, minimize manual errors, and reduce administrative costs linked to traditional checks and invoices.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=254915304

Based on offering, the solutions segment holds the largest market size during the forecast period

The solutions segment of the digital payment market has been classified into payment infrastructure, billing and accounting management, and security, compliance, and fraud prevention management. Major B2B digital payment vendors are gradually adopting smart technologies, such as cloud computing, analytics, and big data, to offer comprehensive solutions to potential customers.

Based on solutions, the billing and accounting management segment is expected to grow with the highest CAGR during the forecast period

Billing and accounting management solutions are integral in the B2B digital payment market, streamlining financial processes, reducing errors, and enhancing overall financial management for businesses. These solutions encompass features like invoicing, payment processing, automated reminders, and expense tracking. They facilitate efficient creation and tracking of invoices, offer diverse payment methods, and provide automated reminders for overdue payments. The ability to categorize expenses, generate comprehensive financial reports, and integrate with accounting software ensures accurate financial insights. Security measures and compliance with regulations safeguard sensitive data, while streamlined approval processes and scalability accommodate diverse business needs. Ultimately, these solutions play a pivotal role in optimizing financial operations, promoting transparency, and supporting informed decision-making in the B2B digital payment landscape.

North America is expected to have the largest market size during the forecast period.

The B2B digital payment market in North America is highly competitive, as the US and Canada have a strong focus on Research and Development (R&D) and innovation. North America has been a global innovator, constantly at the forefront of payment technology along with retail and financial services. The region has always been dependent on the stability and convenience of its well-established payment infrastructure. The widespread adoption of mobile devices, such as smartphones and tablets, and the need to have convenient access to financial solutions have positively affected the B2B digital payment market in North America. The shift from paper-based processes to digital solutions, including digital wallets and virtual cards, was enhancing efficiency and security. Mobile payments gained traction, while blockchain and cryptocurrencies were explored for potential disruption.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=254915304

Unique Features in the B2B Digital Payment Market

B2B digital payments incorporate advanced security measures such as encryption, tokenization, and multi-factor authentication to safeguard transactions. AI-driven fraud detection systems help identify and mitigate fraudulent activities in real-time, ensuring secure transactions.

Unlike traditional payment methods, digital B2B transactions are processed almost instantly, reducing settlement times from days to mere hours or minutes. This leads to improved cash flow management and enhanced business efficiency.

Automation in digital payments minimizes manual intervention by integrating with enterprise resource planning (ERP) and accounting systems. This streamlines invoice processing, reconciliation, and payment approvals, reducing human errors and administrative burdens.

Businesses can access a variety of digital payment methods, including ACH transfers, virtual cards, digital wallets, and blockchain-based payments. This flexibility allows companies to choose the most suitable option based on their transaction needs.

B2B digital payment solutions facilitate seamless international transactions by supporting multiple currencies and complying with global financial regulations. They help businesses reduce foreign exchange risks and transaction costs associated with cross-border payments.

Major Highlights of the B2B Digital Payment Market

Businesses are moving away from traditional paper-based transactions such as checks and invoices toward digital solutions. The adoption of electronic payments reduces processing time, minimizes errors, and enhances overall operational efficiency.

AI-powered automation and blockchain technology are revolutionizing the B2B payment landscape. AI improves fraud detection and workflow automation, while blockchain ensures secure, transparent, and immutable transactions, particularly for cross-border payments.

With globalization, businesses require seamless international payment solutions. Digital B2B payments offer multi-currency support, compliance with international regulations, and reduced transaction costs, making cross-border transactions more efficient.

B2B digital payment solutions are increasingly integrated with ERP, accounting, and financial management systems. This connectivity streamlines invoice reconciliation, cash flow management, and reporting, enabling businesses to maintain better financial control.

Security remains a top priority, with businesses implementing encryption, multi-factor authentication, and AI-driven fraud detection. These measures help prevent unauthorized transactions and ensure compliance with regulatory standards.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=254915304

Top Companies in the B2B Digital Payment Market

Various globally established players, such as PayPal (US), Fiserv (US), FIS (US), Global Payments (US), ACI Worldwide (US), Block (US), MasterCard (US), Visa (US), Payoneer (US), Stripe (US), are dominating the B2B digital payment market. To increase their market share in the B2B digital payment market, these competitors have used a variety of growth methods, including partnerships, agreements, collaborations, new product releases, product enhancements, and acquisitions.

PayPal has established itself as a prominent player in the B2B digital payment market, offering a range of services tailored to businesses. Its services include business accounts, invoicing, checkout integration, debit cards, working capital loans, and a commerce platform. While traditionally associated with consumer transactions, PayPal has made efforts to cater to businesses’ needs for online and in-person payments. With features like customizable invoicing, PayPal Checkout for online payments, and the convenience of in-person transactions through PayPal Here, businesses can seamlessly manage their revenue streams. PayPal’s comprehensive reporting tools aid in tracking finances, while its integration options and APIs empower businesses to embed payment functionalities into their platforms. Moreover, the PayPal Commerce Platform encompasses an array of services catering to different business sizes, spanning payment processing to subscription management.

Fiserv is a leading global financial technology company. It specializes in providing a comprehensive range of solutions and services to diverse segments of the financial industry. Fiserv’s core areas of expertise encompass payment and processing solutions, financial services technology, digital banking, risk and compliance solutions, and wealth management. The company is recognized for its commitment to innovation, continually advancing technology to meet the evolving needs of financial institutions and businesses. Through strategic acquisitions and a strong focus on research and development, Fiserv has solidified its position as a key player in shaping the landscape of financial technology. Fiserv excels in delivering technology-driven answers that cater precisely to businesses’ payment requisites, spanning the spectrum from small enterprises to expansive corporations.

FIS (Fidelity National Information Services): FIS is an American multinational company specializing in financial services technology. Headquartered in Jacksonville, Florida, FIS offers a broad range of financial software and services to banks, credit unions, asset managers, and other financial institutions worldwide. The company’s solutions include core banking systems, payment processing, risk management, and digital banking platforms. FIS is known for its expertise in providing technology solutions that help financial institutions streamline operations, enhance customer experiences, and manage regulatory compliance effectively.

Global Payments Inc.: Global Payments is a leading worldwide provider of payment technology and software solutions headquartered in Atlanta, Georgia, USA. Founded in 2000, the company offers a comprehensive suite of payment processing services, including credit and debit card processing, electronic check conversion, and merchant services. Global Payments serves a diverse range of industries, including retail, hospitality, healthcare, and e-commerce, enabling businesses to accept payments securely and efficiently. The company also provides integrated software solutions for managing payments, fraud prevention, and customer engagement, making it a key player in the global payments industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/b2b-digital-payment-market-254915304.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: B2B Digital Payment Market Recent Trends, Outlook, Size, Share, Top Companies, Industry Analysis, Future Development & Forecast – 2028